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Abstract
Background and aim: Whether cerebral microbleeds cause cognitive impairment remains uncertain. We analyzed
whether cerebral microbleeds are associated with cognitive dysfunction in patients with symptomatic cerebral small
vessel disease, and whether this association is independent of other neuroimaging markers of cerebral small vessel disease.
Methods: We analyzed consecutive patients with MRI-confirmed lacunar stroke included in DNA-Lacunar-2 multicenter
study. Cerebral microbleeds were graded using the Brain Observer Microbleed Rating Scale (BOMBS).
Neuropsychological assessment was performed using the Brief Memory and Executive Test (BMET). We analyzed the
association between cerebral microbleeds, BMET, and the following subdomains: executive function/processing speed
and orientation/memory. We also searched for an independent association between cerebral microbleeds and vascular
cognitive impairment, defined as BMET 13.
Results: Out of 688 included patients, cerebral microbleeds were detected in 192 (27.9%). After adjusting for white
matter hyperintensities severity, lacune count, and other confounders, both the presence and the number of cerebral
microbleeds were significantly associated with impaired cognitive performance [b¼13.0; 95% CI¼ (25.3, 0.6) and
b¼13.1; 95% CI¼ (19.8, 6.4), respectively]. On analysis of specific cognitive domains, associations were present
for executive function/processing speed [b¼5.8; 95% CI¼ (9.3, 2.2) and b¼4.3; 95% CI¼ (6.2, 2.4),
respectively] but not for orientation/memory [b¼0.4; 95% CI¼ (4.0, 3.2) and b¼2.1; 95% CI¼ (4.0, 0.1),
respectively]. We also found an independent association between the presence and the number of cerebral microbleeds
and vascular cognitive impairment [adjusted OR¼ 1.48; 95% CI¼ (1.01, 2.18) and OR¼ 1.43; 95% CI¼ (1.15, 1.79),
respectively].
Conclusion: In a large cohort of symptomatic cerebral small vessel disease patients, after controlling for other
neuroimaging markers of cerebral small vessel disease severity, cerebral microbleeds were associated with cognitive
dysfunction. Executive function and processing speed were predominantly impaired. This might suggest a causal role of
cerebral microbleeds in determining vascular cognitive impairment.
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Introduction
Cerebral microbleeds (CMBs) are perivascular focal
deposits of haemosiderin-laden macrophages, ranging
in diameter between 0.80 and 1.5mm, visible as signal
voids on T2*-weighted gradient echo (GE) and suscep-
tibility weighted imaging (SWI) magnetic resonance
imaging (MRI).1,2 Together with lacunar infarcts,
white matter hyperintensities (WMH) and enlarged
perivascular spaces, CMBs are a recognized
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neuroimaging marker of cerebral small vessel disease
(cSVD).3 CMB frequency increases with age;4 also,
they are common in patients with stroke, cognitive
impairment, and dementia.5,6
Whether CMBs are independently associated with
cognitive impairment in patients with stroke and
cSVD is uncertain, with studies to date giving incon-
sistent results. In patients with previous stroke or TIA,
those with CMBs showed impaired executive function
and this was particularly associated with CMBs in the
frontal region and basal ganglia.7 However, in another
study of stroke patients, CMBs were not associated
with cognitive performance during a four-year follow
up.8 In patients with cSVD and radiological lacunar
stroke and confluent white matter hyperintensities,
CMBs were only associated with cognition when very
frequent.9 Furthermore, the relationship was weakened
after controlling for other markers of cSVD.
A key question when evaluating any association
between CMB and cognition is whether they are inde-
pendent markers of cognition, or merely acting as mar-
kers for other features of cSVD such as lacunar strokes
and WMH which themselves are known to be asso-
ciated with cognition.10,11 Previous studies have
shown strong associations between CMB and both
lacunar infarcts and WMH in patients with cSVD.3,12
It is also uncertain whether CMBs associate particu-
larly with specific cognitive domains. For example,
CMB in cSVD patients in whom the predominant path-
ology is hypertensive arteriopathy might be expected to
associate more strongly with cognitive domains
dependent on subcortical integrity, such as executive
function and processing speed.
To further investigate these relationships, we deter-
mined associations between CMB and cognition in a
large cohort of MRI confirmed lacunar stroke patients.
Furthermore, we evaluated whether any associations




Patients were studied who had been recruited to the
prospective DNA-Lacunar-2 study, an ongoing multi-
center study recruiting patients with lacunar stroke
from 51 hospitals across the UK. Participants recruited
between 10 August 2016 and 1 April 2020 were
included in the analysis for this paper. The inclusion
criteria were a clinical lacunar syndrome with an ana-
tomically corresponding lacunar infarction confirmed
on brain MRI, and the MRI performed within one
year of stroke. Study participants were recruited
within two years since the stroke onset; those showing
any other potential cause of stroke other than cSVD
(including large artery disease causing a sten-
osis> 50%, or cardio-embolic source) or with any
other potential cause of white matter disease (such as
multiple sclerosis) were excluded. Further inclusion cri-
teria for this analysis were: the availability of hemosi-
derin-sensitive sequences on MRI; and the availability
of a complete assessment of cognitive functions
through the Brief Memory and Executive Test
(BMET).
At the time of inclusion, a large number of clinical
and laboratory variables were prospectively collected
for each participant using prespecified forms.
Information about pre-stroke functional status, pre-
existing vascular risk factors, and medication at the
time of the stroke were also recorded. The definitions
of these variables are available in the ‘‘e-Methods’’ sec-
tion in the Supplementary Material.
Neuroimaging variables
Clinical MRI scans were used. After recruitment, all
original MR images were centrally reviewed with case
histories by a neurologist to confirm eligibility. The
severity of cSVD was determined radiologically at the
time of the eligibility review. The number of total lacu-
nar infarcts, including both acute lacunar lesions hyper-
intense on DWI and cavitated lacunar lesions on
FLAIR/T1 sequences, was determined. A lacune on
FLAIR/T1 was defined as a cerebrospinal fluid-filled
cavity, 3–15mm in diameter, with a surrounding rim
of high signal intensity following a perforator artery
distribution.13 The Fazekas scale was used to grade
the extent of WMH on T2-FLAIR.14 This was deter-
mined separately for both for the periventricular (PV)
and deep white matter (DWM) regions, each of them
giving a 0–2 subscore; an overall WMH score (0–3) was
also determined.
The presence, total count, and location of CMBs
were graded by a single neurologist (SN) using the
Brain Observer Microbleed Rating Scale (BOMBS).15
CMBs were defined as focal area of very low intensity,
<10mm of diameter, on SWI/GE sequences.
Hypointense lesions were excluded if they appeared to
be vascular flow voids (based on sulcal location or
linear shape), basal ganglia mineralization, or artifacts
from an adjacent bone or sinus. All uncertain cases
were reviewed with a consultant neuroradiologist
(AM) to reach a consensus. Only CMBs meeting the
BOMBS certain criteria were analyzed. The CMBs
location was described according to the seven anatom-
ical brain regions proposed by the scale, and also
grouped into the following three sub-categories: cor-
tical (for patients having CMB(s) in the cortex only),
subcortical (for patients having CMB(s) in the
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subcortical white matter, basal ganglia, internal/exter-
nal capsule, thalamus, brainstem, and/or cerebellum),
and mixed (cortical and subcortical CMBs) distribu-
tion. The identification of CMB lesions was blinded
to the assessment of cognitive function.
Neuropsychological assessment
All included patients were assessed with the BMET.
This is a short cognitive screening tool, designed and
validated to be sensitive for the detection of vascular
cognitive impairment (VCI) in cSVD patients.16–18 The
test is freely available at www.bmet.info. It includes a
number of subscores, each ranked on an age normative
scale from 0 to 2, which is used to form a total score
(ranged on a scale from 0 to 16). A BMET total score of
13 has been previously validated to define the pres-
ence of VCI.16 The test performance can be subdivided
into two major cognitive domains clusters, executive
functioning/ processing speed (EF/PS) and orientation/
memory (O/M), each with a score ranging from 0 to 8.
The EF/PS subscore is calculated from the tasks:
(i) letter-number matching, (ii) motor sequencing,
(iii) letter sequencing, and (iv) number-letter sequen-
cing, while the O/M subscore from the tasks: (i) orien-
tation, (ii) five-item repetition, (iii) five-item recall, and
(iv) five-item recognition memory.
Statistical analysis
In the study population, ordinal and continuous vari-
ables were summarized with median and interquartile
range (IQR), categorical ones with absolute counts and
percentage. Demographics, clinical, and radiological
variables in patients with and without CMBs, and in
patients with and without VCI, were compared with
appropriate tests: we used the Mann–Whitney test to
compare continuous data, the chi-square test for cat-
egorical data, and the chi-square test for trend for ordi-
nal data.
The relationship between CMBs and the cognitive
performance on the BMET was investigated with multi-
variate linear regression models. Two models were
tested: in model A we adjusted for age, sex, time from
stroke onset to recruitment, years of education, and
modified Rankin score (mRS) at consent time; in
model B we added WMH severity score and lacune
count as further variables for adjustment. We applied
a logarithm transformation (base¼ 10; start¼ 1) to
reduce the positively skewed distribution for CMBs
total number, and the squared transformation for the
negatively skewed distribution of the BMET total score
and its sub-scores. A nonparametric model (Kernel
regression) was also fitted to assess the sensitivity of
the results, adjusting for the same covariates. As further
sensitivity analyses, we studied the association between
CMBs and cognition in the subgroup of patients
included within the median onset to randomization
time and in the subgroup of patients without previous
stroke/TIA.
Lastly, a logistic regression model was used to search
for independent associations between CMBs (presence,
number and location) and VCI. The same adjustments
as used in models A and B were applied.
Statistical analyses were performed using STATA
software. p< 0.05 were regarded as significant.
Standard protocol approvals and patient consents
The study was approved by the East of England -
Cambridge Central Research Ethics Committee (16/
EE/0201). All study participants signed informed con-
sent form at time of recruitment.
Data availability statement




During the study period, 903 patients with MRI-con-
firmed lacunar stroke were recruited. One hundred
forty-eight patients (16.4%) were excluded because of
the absence of hemosiderin-sensitive sequences on MRI
and 67 (7.4%) additional patients were excluded due to
missing/incomplete neuropsychological assessment (see
flowchart in Supplementary Figure 1). Therefore, 688
patients were included in this analysis. The number of
the included patients in each participating center is
listed in Supplementary Table 1. The median age of
the study population was 64 years (IQR¼ 55–74), and
36% were female. The median time from stroke onset
to recruitment was 37 (5–104) days (Table 1).
At least one CMB was detected in 192 (27.9%)
patients. Of these, 57 (29.7%) patients had 1 CMB,
60 (31.3%) had 2 to 4, 37 (19.3%) had 5 to 9, 25
(13.0%) had 10 to 19, and 13 (6.8%) had 20 CMBs.
The most frequent CMBs locations were the cortex
(with 55% of patients having at least one CMB in
this location), the subcortical white matter (45% of
patients) and the thalamus (35% of patients;
Supplementary Table 2). The overall distribution was
strictly subcortical in 87 (45.3%), mixed (cortical and
subcortical) in 78 (40.6%) and strictly cortical in 27
(14.1%) patients.
Compared to patients without CMBs, patients with-
 1 CMB(s) showed more hypertension (n¼ 157, 82%
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Table 1. Demographics, vascular risk factors, clinical, and radiological characteristics of the included patients and in the subgroups
of patients with and without CMBs. Ordinal and continuous variables are summarized with median and interquartile range (IQR),




Patients with 1 CMB(s)
(N¼ 192)
Patients without
CMBs (N¼ 496) p
Age at stroke onset 64 (55–74) 67 (58–76) 64 (55–73) 0.064
Sex, female 247 (35.9%) 64 (33.3%) 183 (36.9%) 0.382
mRS 1 (0–2) 1 (0–2) 1 (0–2) 0.081
Stroke onset to consent time, days 37 (5–104) 26 (5–88) 44 (5–110) 0.149
Risk factors
HTN 509 (74.0%) 157 (81.8%) 352 (71.0%) 0.004*
Dyslipidaemia 458 (66.6%) 130 (67.7%) 328 (66.1%) 0.694
DM 151 (22.0%) 37 (19.3%) 114 (23.0%) 0.291
Active smoking 135 (19.6%) 35 (18.2%) 100 (20.1%) 0.567
MI 44 (6.4%) 13 (6.8%) 31 (6.3%) 0.802
Depression 113 (16.4%) 36 (18.9%) 77 (15.5%) 0.306
Migraine 124 (18.0%) 29 (15.1%) 95 (19.2%) 0.215
BMI 27 (24–31) 27 (24–31) 27 (24–30) 0.449
Previous stroke/TIA 73 (10.6%) 35 (18.2%) 38 (7.7%) <0.001*
Pre-stroke medications
Antiplatelet 168 (24.5%) 58 (30.4%) 110 (22.2%) 0.026*
Anticoagulant 9 (1.3%) 3 (1.6%) 6 (1.2%) 0.711
Statin 231 (33.6%) 74 (38.5%) 157 (31.7%) 0.089
Antihypertensive 338 (49.2%) 105 (54.7%) 233 (47.1%) 0.073
IVT 38 (5.5%) 8 (4.2%) 30 (6.1%) 0.332
Neuroimaging features
Lacune count score
1 (1–2 lesions) 510 (74.2%) 96 (50.0%) 414 (83.6%) <0.001*
2 (3–5 lesions) 129 (18.8%) 65 (33.9%) 64 (12.9%)
3 (>5 lesions) 48 (7.0%) 31 (16.2%) 17 (3.4%)
WMH score
0 (absent) 172 (25.0%) 21 (10.9%) 151 (30.5%) <0.001*
1 (mild) 216 (31.4%) 42 (21.9%) 174 (35.2%)
2 (early confluent) 207 (30.1%) 76 (39.6%) 131 (26.5%)
(continued)
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vs. n¼ 352, 71%, p¼ 0.004) and previous history of
stroke/TIA (n¼ 35, 18% vs. n¼ 38, 8%, p< 0.001),
and were more frequently on antiplatelet therapy at
the time of the stroke (n¼ 58, 30% vs. n¼ 110, 22%,
p< 0.001; Table 1). They did not differ from patients
without CMBs in age, sex, time since stroke, or vascu-
lar risk factors other than hypertension (Table 1). On
MRI, the presence of CMB(s) was associated with
higher lacune count score (p< 0.001) and higher total,
PV, and DWM WMH scores (all p< 0.001).
In the overall population, median BMET total score
was 14 (IQR¼ 12–16), and VCI was present in 282
(41%) patients. Characteristics of subjects with and
without VCI are presented in Supplementary Table 3.
Results from the univariate analysis showed that
patients with VCI, compared to patients without,
were predominantly male (n¼ 197, 70% vs. n¼ 244,
40%, p¼ 0.009), had higher frequency of diabetes
(n¼ 80, 28% vs. n¼ 71, 18%, p< 0.001) and higher
BMI (28 vs. 26, p¼ 0.020). There was no significant
difference regarding age or level of education. On neu-
roimaging, VCI was significantly associated with WMH
load, higher lacune count, and both the presence and
the number of CMBs.
CMBs, cognitive performance, and cognitive
domains
After adjusting for clinical confounders (model A,
Table 2), there was a significant association between
both the presence and the total count of CMBs with
poorer performance on the total BMET score
[b¼25.5, 95% CI¼ (37.0, 14.0) and b¼19.3,
95% CI¼ (25.4, 13.2), respectively]. After further
adjusting for WMH severity and lacune count (model
B, Table 2), both the presence and number of CMBs
remained significantly associated with impaired cogni-
tive performance [b¼13.0, 95% CI¼ (25.3, 0.6)
and b¼13.1, 95% CI¼ (19.8, 6.4), respectively].
CMBs count in the top decile (CMBs 5, N¼ 75,
10.9%) was strongly associated with cognitive function
[b¼50.6, 95% CI¼ (67.1, 34.1)] (model A,
Table 2); controlling for other MRI measures reduced
the strength of the association but it remained signifi-
cant [b¼36.6, 95% CI¼ (53.7, 19.4)] (model B,
Table 2).
On analysis of specific cognitive domains, significant
negative associations were present between both the
presence and the total count of CMBs with the EF/
PS subscore [b¼5.8; 95% CI¼ (9.3, 2.2) and
b¼4.3; 95% CI¼ (6.2, 2.4), respectively, in the
fully adjusted model B, Table 2]. In contrast, no asso-
ciation was found between CMBs (presence or total
count) and performance on the O/M subscore.
However, CMB count in the top decile was associated
with worse performance on both EF/PS and O/M
domains [b¼5.8; 95% CI¼ (9.3, 2.2) and
b¼4.3; 95% CI¼ (6.2, 2.4), respectively, in the
fully adjusted model B, Table 2].
Results from a nonparametric regression model con-
firmed the associations found in the linear regression
model: CMBs total count was related to lower scores
on total BMET and on EF/PS subscore, but was not
associated with the O/M subscore (see Supplementary
Table 4).
As sensitivity analyses, the analysis of patients
included within 37 days from stroke onset (N¼ 346)
and the analysis of patients without previous stroke/
TIA (N¼ 614) confirmed the main results on the
entire population, i.e. both the presence of any CMBs
and the CMBs total count were independently asso-
ciated with lower scores on EF/PS subscore of the
BMET after full adjustment for clinic-radiological vari-
ables, but not with the O/M subscore (Supplementary
Table 5).
In view of the association between CMBs and EF/
PS, we investigated associations with specific brain
regions. Significant associations between the presence
of any CMB and worse performance on EF/PS sub-
score were present for the deep white matter and brain-
stem, after controlling for risk factors and MRI
markers of cSVD [model B, b¼4.6, 95%
CI¼ (9.2, 0.1 and b¼8.0, 95% CI¼ (16.0,





Patients with 1 CMB(s)
(N¼ 192)
Patients without
CMBs (N¼ 496) p
3 (confluent) 92 (13.4%) 53 (27.6%) 39 (7.9%)
PV subscore 1 (0–2) 2 (1–3) 1 (0–2) <0.001*
DWM subcore 1 (0–2) 2 (1–2) 1 (0–2) <0.001*
mRS: modified Rankin scale (at the time of consent); HTN: hypertension; DM: diabetes mellitus; MI: myocardial infarction; BMI: body mass index; TIA:
transient ischemic attack; IVT: intravenous thrombolysis; WHM: white matter hyperintensity; PV: periventricular; DWM: deep white matter.
*Indicates significant result.
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Table 2. Associations between CMBs (presence, number, and top-decile) and cognitive functions, expressed by BMET total score
and O/M and EF/PS sub-scores. Results from two linear regression models are presented: model A included age, sex, stroke onset to
consent time, education, and mRS at consent time as variables for adjustment; in model B we added WMH score and lacune count as
further variables for adjustment. A squared transformation of cognitive scores and a logarithmic transformation of CMBs number
were used. Results are expressed as b coefficient and 95% CI
Cognitive test Model A (clinical) p Model B (clinic-radiological) p
Presence of 1 CMB(s) (vs. absence)
BMET total score 25.5 (37.0, 14.0) <0.001* 13.0 (25.3, 0.6) 0.040*
O/M subscore 3.4 (6.7, 0.0) 0.051 0.4 (4.0, 3.2) 0.826
EF/PS subscore 8.4 (11.6, 5.1) <0.001* 5.8 (9.3, 2.2) 0.001*
CMBs total count
BMET total score 19.3 (25.4, 13.2) <0.001* 13.1 (19.8, 6.4) <0.001*
O/M subscore 1.4 (3.8, 0.9) 0.233 2.1 (4.0, 0.1) 0.115
EF/PS subscore 5.6 (7.3, 3.8) <0.001* 4.3 (6.2, 2.4) <0.001*
CMBs 5
BMET total score 50.6 (67.1, 34.1) <0.001* 36.6 (53.7, 19.4) <0.001*
O/M subscore 9.6 (14.4, 4.8) <0.001* 6.5 (11.6, 1.5) 0.012
EF/PS subscore 13.9 (18.6, 9.2) <0.001* 10.7 (15.6, 5.8) <0.001*
CMB: cerebral microbleed; BMET: brief memory and executive test; O/M: orientation/memory; EF/PS: executive function/processing speed.
*Indicates significant result.
Table 3. Associations between cerebral microbleeds (CMBs) location and executive functions/processing speed (EF/PS) perform-
ance, and orientation and memory (O/M) tasks
EF/PS subscore O/M subscore
CMB location
Beta coefficient (95% CI)
from model B p
Beta coefficient (95% CI)
from model B p
CMBs in the cortex 1.6 (5.0, 1.7) 0.350 1.7 (5.1, 1.7) 0.328
CMBs in the subcortical WM 4.6 (9.2, 0.1) 0.044* 3.8 (8.3, 0.8) 0.106
CMBs in the basal ganglia 2.0 (7.3, 3.3) 0.460 0.3 (5.1, 5.6) 0.917
CMBs in the int/ext capsule 10.8 (0.1, 21.6) 0.051 3.2 (7.6, 14.1) 0.560
CMBs in the thalamus 2.9 (8.7, 2.9) 0.322 0.1 (5.9, 5.7) 0.975
CMBs in the brainstem 8.0 (16.0, 0.1) 0.049* 0.5 (7.5, 8.5) 0.906
CMBs in the cerebellum 1.5 (3.9, 6.8) 0.591 1.5 (3.9, 6.8) 0.591
*Indicates significant result.
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regions. CMBs in the internal and/or external capsule
were associated with better EF/PS, even if the associ-
ation did not reach the statistical significance [model B,
b¼ 10.8, 95% CI¼ (0.1, 21.6), Table 3]. No associ-
ations were seen for the O/M subscore (Table 3).
CMBs and vascular cognitive impairment
Logistic regression models were used to determine the
associations between the presence, number, and loca-
tion of CMBs with VCI, as shown in Table 4. The pres-
ence of any CMBs, the total number of CMBs and
presence of 5 CMBs were all independently related
to VCI (odds ratio, OR¼ 2.01, p¼ 0.007; OR¼ 1.67,
p< 0.001; OR¼ 4.39, p< 0.001, respectively) after
adjusting for age, sex, education, stroke onset to con-
sent time, and mRS at consent time (model A). The
introduction of lacune count and WMH grade as fur-
ther covariates for adjustment (model B) reduced the
strength of these associations, but they still all remained
significant (OR¼ 1.48, p¼ 0.047; OR¼ 1.43, p< 0.001;
OR¼ 3.18, p< 0.001, respectively).
Regarding CMB location, the presence of strictly
subcortical CMB was an independent predictor of
VCI after covarying for risk factors and other MRI
markers of cSVD (OR¼ 2.73, p¼ 0.044 in model B).
In contrast, there was no similar association seen for
strictly cortical or mixed distribution CMB. Looking at
associations with specific brain regions, significant asso-
ciations between CMB and VCI were seen for the deep
white matter and brainstem, after controlling for risk
factors and MRI markers of cSVD (model B; Table 4).
Discussion
In a large cohort of symptomatic cSVD patients, CMBs
were associated with both impaired cognition and VCI.
Importantly, this association persisted after controlling
Table 4. Relationship between cerebral microbleeds (CMBs; presence, total count, and top-decile) and VCI. Results are presented
for model A (clinical adjustment) and model B (clinic-radiological adjustment), and are expressed as OR and 95% CI
CMB
Presence of VCI (N¼ 282)
Model A (clinical) p Model B (clinic-radiological) p
Presence 1 CMB(s) 2.01 (1.41, 2.88) 0.007* 1.48 (1.01–2.18) 0.047*
CMBs total count 1.67 (1.37, 2.01) <0.001* 1.43 (1.15–1.79) 0.001*
Presence 5 CMBs 4.39 (2.52, 7.66) <0.001* 3.18 (1.78–5.68) <0.001*
CMBs location
CMBs in the cortex 1.23 (0.85–1.81) 0.268 1.12 (0.76–1.65) 0.539
CMBs in the subcortical WM 1.80 (1.06–3.06) 0.031* 1.67 (1.03–2.85) 0.044*
CMBs in the basal ganglia 1.21 (0.66–2.25) 0.535 1.11 (0.59–1.83) 0.753
CMBs in the int/ext capsule 0.26 (0.08–0.90) 0.034* 0.29 (0.08–1.01) 0.051
CMBs in the thalamus 1.16 (0.59–2.23) 0.679 1.03 (0.52–2.02) 0.934
CMBs in the brainstem 3.62 (1.38–9.53) 0.009* 3.28 (1.24–8.67) 0.017*
CMBs in the cerebellum 1.06 (0.57–1.97) 0.851 0.98 (0.53–1.83) 0.950
CMB distribution
Subcortical CMBs 3.01 (1.89–8.98) 0.033* 2.73 (1.03–7.27) 0.044*
Mixed CMBs 1.39 (0.54–3.60) 0.493 1.20 (0.54–3.65) 0.489
reference category¼ cortical CMBs.
*Indicates significant result.
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for other MRI markers of cSVD, suggesting that CMB
are independently related to cognitive impairment and
therefore may play a causal role. The association
between CMBs and cognitive dysfunction was strongest
in those with greater number of CMBs, was particularly
related to subcortical CMBs, and strongest with the
executive function and processing speed cognitive
domain.
Whether CMBs are independently related to cogni-
tion in cohorts with cerebrovascular disease and cSVD
has been uncertain, with previous smaller studies
reporting inconsistent results.7–9,19 Importantly, associ-
ations reported in a number of studies could merely
reflect CMBs acting as a marker of more severe disease
rather than an independent association. In our homo-
genous cohort of patients with cSVD who presented
with a lacunar stroke, we confirmed an independent
relationship between the presence of CMBs and cogni-
tive impairment, which remained significant after
adjusting for the number of lacunar infarcts and the
severity of WMH. This finding provides support that
CMBs are independent contributors to cognitive
impairment.
Our study showed that cognition was most impaired
in patients with large numbers of CMBs. In the sub-
group of patients having at least five CMBs (corres-
ponding to the top decile distribution) we found the
lowest BMET scores, lowest EF/PS and O/M sub-
scores, and a higher frequency of VCI. These findings
are in line with previous studies showing that the pres-
ence of a high CMB count was associated with an
increased risk of cognitive deterioration, both in cere-
brovascular patients9,19,20 and in the general popula-
tion.21–23 This result may suggest a threshold effect of
CMBs burden on cognition, with higher number of
lesions being associated with more severe and multi-
domains cognitive decline.
Our analysis also suggested that the effect of CMBs
on cognition may depend on CMB location, with VCI
being mostly associated with subcortical lesions. In par-
ticular, CMBs located in the subcortical white matter
and in the brainstem showed the stronger relationship
with the impairment of executive function and process-
ing speed. These associations are consistent with the
hypothesis that cerebral microvascular damage prefer-
entially affects white matter and subcortical gray
matter, ultimately leading to disruption of integrity of
fronto-subcortical circuits and interfering with cogni-
tion.23,24 Lesions in the brainstem have been implicated
in executive dysfunction. Previous reports suggested
that patients with pontine brain infarcts frequently
had executive dysfunction,25 and that CMBs in the
pons were associated with worse cognitive performance
in CADASIL patients.26 These findings are in line with
our results, lending support to the hypothesis that
disturbance of the frontal-subcortical circuits, including
projections into the brainstem, could be responsible for
the executive dysfunction in patients with lacunar
stroke.
The cognitive impact of CMBs according to their
topographic distribution may be dependent on the
underlying vascular pathology: while in population-
based studies higher number of strictly lobar CMBs,
presumably resulting from cerebral amyloid angiopa-
thy, were related to cognitive decline and dementia,27,28
in our cohort of patients with stroke and cSVD, the
presence of CMBs in deep regions, resulting primarily
from hypertensive arteriopathy, was associated with
greater decline in the executive functions, with relative
sparing of memory and orientation tasks.
Mechanisms by which CMBs influence cognitive
function remain speculative. The strong association
we found between CMBs and cognition, which was
independent of other neuroimaging markers of cSVD,
suggest that CMBs are not simply a marker for the
severity of small vessel disease, but might have a
causal impact on cognitive function. Previous studies
have suggested that CMBs may cause a direct damage
to white matter tracts, with subsequent disconnection
of functionally important cortical–subcortical cir-
cuits.7,19 Recent studies using diffusion tensor imaging
and tractography have suggested the disruption of com-
plex brain networks dependent on white matter connec-
tions plays a central role in the cognitive impairment
seen in cSVD.29,30 The disruption of brain networks
involving the frontal lobe and periventricular white
matter was important to determine executive dysfunc-
tion and cognitive impairment seen in cSVD, and this
may also be the case for CMBs.31,32
Another possible pathophysiological mechanism by
which CMBs could impair cognition is suggested by
studies from animal models, which reported that
CMBs induced functional and structural disturbances
in the surrounding brain environment: experimentally
induced microbleeds disrupted the function of nearby
neurons and astrocytes,33 and promoted an inflamma-
tory response via microglia proliferation and migra-
tion,34 although most of these effects were transient.
Alternatively, CMBs might relate to cognition via an
indirect effect, through an arteriolar narrowing leading
to cerebral hypoperfusion and microischemic
damage.35 In this latter scenario, higher number of
CMBs may thus indicate more extensive and severe
subclinical microvascular damage.
Our study has a number of strengths. These include
the large number of prospectively collected patients, the
homogenous characteristics of the included population
(with all patients showing at least a recent lacunar
stroke confirmed on MRI), and the systematic assess-
ment of all included patients with the same
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neuropsychological test (BMET). The BMET has been
shown to be more sensitive to the cognitive deficit in
patients with cSVD than the Mini–Mental State
Examination and the Montreal Cognitive Assessment
test, and also allows the analysis of different cognitive
subdomains, in which we showed stronger associations
with the EF/PS domain.24
There are also some limitations. First, the cross-sec-
tional design of our study limits the capability to val-
idate a causal relationship between CMBs and
cognition, and longitudinal studies in large cohort of
cSVD are required. Second, the number of included
patients varied greatly across the participating centers,
which might have introduced some center-effects in the
analysis; we tried to minimize this by introducing a
BMET training for each site members and by perform-
ing a central revision of all brain MRIs. Third, we used
clinical scans performed on different scanners which
included both GE and SWI sequences. However, this
is likely to have reduced to the power to detect associ-
ations and despite this we were able to detect strong
associations between CMB and cognition. Lastly, we
used a visual rating of WMH, which could be less sen-
sitive to the pathology burden compared to the volu-
metric measures of WMH.
Conclusion
We demonstrated that CMBs exhibit a strong associ-
ation with VCI, especially in the domains of executive
functions and processing speed. This association was
independent of other neuroimaging markers of cSVD,
suggesting a potential role of CMBs in the pathophysi-
ology of cognitive deterioration. A direct tissue damage
on white matter tracts, rather than or in addition to
underlying cSVD, may account for the detrimental
effects of CMBs on cognition. Further large longitu-
dinal studies are needed to confirm our conclusions.
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